What is William Blair's Estimate for CNTX Q1 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for Context Therapeutics in a research report issued to clients and investors on Tuesday, April 29th. William Blair analyst M. Phipps expects that the company will post earnings per share of ($0.08) for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics' Q3 2026 earnings at ($0.08) EPS.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01.

CNTX has been the subject of a number of other reports. Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. D. Boral Capital reissued a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Tuesday, April 29th. Finally, JMP Securities started coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Context Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $6.17.

Context Therapeutics Price Performance

Shares of Context Therapeutics stock traded up $0.01 on Wednesday, hitting $0.87. 30,000 shares of the company's stock traded hands, compared to its average volume of 300,208. The firm's 50-day moving average price is $0.78 and its two-hundred day moving average price is $1.16. The stock has a market capitalization of $78.01 million, a PE ratio of -0.96 and a beta of 2.18. Context Therapeutics has a one year low of $0.55 and a one year high of $2.75.

Institutional Trading of Context Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CNTX. Jane Street Group LLC acquired a new stake in Context Therapeutics in the 4th quarter valued at $29,000. Citadel Advisors LLC bought a new stake in Context Therapeutics during the fourth quarter worth about $31,000. Shay Capital LLC acquired a new position in Context Therapeutics during the fourth quarter valued at approximately $52,000. Clear Harbor Asset Management LLC grew its stake in Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock valued at $61,000 after purchasing an additional 21,804 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Context Therapeutics during the 4th quarter worth approximately $94,000. Institutional investors and hedge funds own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.